ClinicalTrials.gg
CompletedNCT07695805Updated Nov 20, 2026

Evaluation of the Effect of Combined Use of Cosmetic Products for Dry and Itchy Skin.

An interventional study of Shower oleogel and body lotion and Shower gel and body lotion in Dry Skin, sponsored by Lacer S.A.. Completed at 1 site in Portugal. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Lacer S.A. (part of Italfarmaco) · Not applicable, Interventional, and Other

How we know

Updated Nov 20, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The goal of this study is to learn if combined use of shower oleogel and body lotion works to improve skin itching and dryness in adults. It will also learn about its safety. The main question it aims to answer is:

  • Does the products use improves skin hydration and itching? Researchers will compare shower oleogel and body lotion to a commercially available shower gel and the body lotion to see if the combined use is more efficient than use of body lotion alone.

Participants will:

  • Use assigned products every day for 1 month
  • Visit the CRO for checkups and tests on established schedule
02

Conditions studied

  • Dry Skin
03

In context

Lead sponsor

Lacer S.A. is the lead sponsor of 13 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 18-70 years old
  • Gender: both
  • Sensitive skin and 30% to 50% with atopic tendency (scored 8-12)
  • With dry or very dry skin on the body
  • With presence of itching due to different origins: contact/friction with fabrics, hard water, atopic tendency, dry skin, etc.

Exclusion criteria

Exclusion Criteria:

  • cutaneous marks on the experimental areas, which could interfere with the assessment of skin reactions (pigmentation troubles, scar elements, over-developed pilosity, ephelides and naevi in too great quantity, sunburn),
  • allergy or reactivity to products of the same category than the tested one,
  • with history of malignant melanomas (Dubreullh melanosis…)
  • unbalanced hormonal treatment,
  • forecast of initiation of an hormonal treatment or change of the usual hormonal treatment during the study or 3 months before the starting of the study,
  • forecast of intensive sun or UVA exposure (UV lamps) during the test period,
  • breast-feeding or pregnancy,
  • treatment with Vitamin A acid or its derivatives stopped less than 3 months before the beginning of the study,
  • treatment with anti-stretch, firming, slimming or anti-cellulite products stopped less than 3 months before the beginning of the study,
  • diet stopped less than 3 months before the beginning of the study,
  • drugs likely to produce an increase or reduction in body weight,
  • under anti-cellulite treatment: mesotherapy, electrotherapy, ionisation, ultrasonotherapy, relaxation, acupuncture, hydrotherapy, lymphatic drainage, massage, sauna,…,
  • neither antibiotic, anti-allergic, anti-inflammatory treatment nor treatment with patent medicines containing Vitamin A acid or its derivatives before and during the study (if therapeutic requirement: exclusion foreseen),
  • systemic disorders: Cardiovascular, pulmonary, digestive, neurologic, psychiatric, genital, urinary, haematological, endocrine
  • individuals who have undergone a bilateral mastectomy with lymph node removal, a unilateral mastectomy with lymph node removal within the last year, or a bilateral axillary lymph node removal,
  • individuals with a history of immune deficiency or auto-immune disease, treated for within 6 months prior to enrollment or who are currently under treatment for asthma or diabetes,
  • forecast of vaccination during the test period or last vaccination within 3 weeks before the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    shower oleogel and body lotion

    shower oleogel and body lotion will be used daily for 28 days

    Other: Shower oleogel and body lotion

  • Active comparator
    shower gel and body lotion

    shower gel and body lotion will be used daily for 28 days

    Other: Shower gel and body lotion

Interventions

  • OtherShower oleogel and body lotion

    Daily use of shower oleogel and body lotion for 28 days

  • OtherShower gel and body lotion

    Daily use of shower gel and body lotion

06

What researchers measure

Primary outcomes

  1. Change from Baseline in the rate of skin hydration (capacitance measured by Corneometer) at 4 weeks

    Time frame: From enrollment to the end of the study at 4 weeks

Secondary outcomes

  1. Change from Baseline in the rate of skin barrier function (TEWL evaluated by Tewameter) at 4 weeks.

    Time frame: From enrollment to the end of the study at 4 weeks

07

Study locations

1 site
  • PhD Trials
    Lisbon, Lisbon District 1750-182, Portugal
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Only summary of the results to support the publication will be shared. No complete study documents will be shared.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jul 2026 to primary completion in Aug 2026, 1 month.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: primary completion Sep 2026 → Aug 2026 and completion Sep 2026 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2026
First posted
Jul 10, 2026
StartActual
Jul 1, 2026
Primary completionActual
Aug 10, 2026was Sep 2026
CompletionActual
Aug 10, 2026was Sep 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Completed
changed Nov 20, 2026
Primary completion
Sep 2026→Aug 10, 2026 (actual)
Nov 20, 2026
Study completion
Sep 2026→Aug 10, 2026 (actual)
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Not yet recruiting→Completed
    Primary completion Sep 2026→Aug 10, 2026 (now actual)
    Study completion Sep 2026→Aug 10, 2026 (now actual)
    + 1 other change: contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07695805
Lead sponsor
Lacer S.A.
Responsible party
Sponsor
First posted
Jul 10, 2026
Start date
Jul 1, 2026
Primary completion
Aug 10, 2026
Completion
Aug 10, 2026
Last update
Nov 20, 2026

Study contacts

Perdo Contreiras
principal investigator · PhD Trials

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion